Accéder au contenu
Merck

Characterization of Dopaminergic System in the Striatum of Young Adult Park2-/- Knockout Rats.

Scientific reports (2018-01-26)
Jickssa M Gemechu, Akhil Sharma, Dongyue Yu, Yuran Xie, Olivia M Merkel, Anna Moszczynska
RÉSUMÉ

Mutations in parkin gene (Park2) are linked to early-onset autosomal recessive Parkinson's disease (PD) and young-onset sporadic PD. Park2 knockout (PKO) rodents; however, do not display neurodegeneration of the nigrostriatal pathway, suggesting age-dependent compensatory changes. Our goal was to examine dopaminergic (DAergic) system in the striatum of 2 month-old PKO rats in order to characterize compensatory mechanisms that may have occurred within the system. The striata form wild type (WT) and PKO Long Evans male rats were assessed for the levels of DAergic markers, for monoamine oxidase (MAO) A and B activities and levels, and for the levels of their respective preferred substrates, serotonin (5-HT) and ß-phenylethylamine (ß-PEA). The PKO rats displayed lower activities of MAOs and higher levels of ß-PEA in the striatum than their WT counterparts. Decreased levels of ß-PEA receptor, trace amine-associated receptor 1 (TAAR-1), and postsynaptic DA D2 (D2L) receptor accompanied these alterations. Drug-naive PKO rats displayed normal locomotor activity; however, they displayed decreased locomotor response to a low dose of psychostimulant methamphetamine, suggesting altered DAergic neurotransmission in the striatum when challenged with an indirect agonist. Altogether, our findings suggest that 2 month-old PKO male rats have altered DAergic and trace aminergic signaling.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-récepteur dopaminergique D2, domaine cytoplasmique, forme longue, Chemicon®, from rabbit
Sigma-Aldrich
Anti-Dopamine D2 Receptor Antibody, serum, Chemicon®
Sigma-Aldrich
Anti-Monoamine Oxidase B (C-terminal) antibody produced in rabbit, affinity isolated antibody, ~1.5 mg/mL, buffered aqueous solution